{"id":3832,"date":"2025-03-31T18:11:50","date_gmt":"2025-03-31T18:11:50","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/chlorpromazine-hydrochloride-txt\/"},"modified":"2025-03-31T18:11:50","modified_gmt":"2025-03-31T18:11:50","slug":"chlorpromazine-hydrochloride-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/chlorpromazine-hydrochloride-txt\/","title":{"rendered":"Chlorpromazine hydrochloride.txt"},"content":{"rendered":"<h1>Chlorpromazine hydrochloride<\/h1>\n<p><H3>  CLINICAL USE <\/H3><\/p>\n<li>Anti-emetic\n<li>Anxiolytic\n<li>Antipsychotic\n<li>Hiccups <H3> DOSE IN NORMAL RENAL FUNCTION  <\/H3>\n<li>Anti-emetic: Oral: 10\u201325 mg every 4\u20136 hours \u2014IM: 25\u201350 mg every 3\u20134 hours\n<li>Antipsychotic, anxiolytic: Oral: 25 mg every 8 hours (or 75 mg at  \u2014night) initially; increase as necessary; usual maintenance dose 75\u2013300 mg daily (up to 1 g daily)\n<li>IM: 25\u201350 mg every 6\u20138 hours\n<li>\n<li>Induction of hypothermia: 25\u201350 mg every  6\u20138 hours\n<li>Hiccups: Oral: 25\u201350 mg every 6\u20138 hours\n<li>PR (unlicensed): 100 mg every 6\u20138 hours <H3>  PHARMACOKINETICS    <\/H3><LI> Molecular weight &amp;nbsp  &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp  &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp :355.3<\/li>\n<li>  %Protein binding  &amp;nbsp &amp;nbsp &amp;nbsp  &amp;nbsp  &amp;nbsp  &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp :95\u201398<\/li>\n<li>  %Excreted unchanged in urine &amp;nbsp &amp;nbsp : &lt;1<\/li>\n<p><LI> Volume of distribution (L\/kg) &amp;nbsp &amp;nbsp &amp;nbsp :7\u2013201<\/li>\n<p><LI>half-life \u2013 normal\/ESRD (hrs)&amp;nbsp &amp;nbsp &amp;nbsp :23\u201337\/Unchanged<H3>  DOSE IN RENAL IMPAIRMENT <\/H3> <H4>GFR (mL\/MIN)<\/H4><LI> 20 to 50  &amp;nbsp &amp;nbsp : Dose as in normal renal function <LI> 10 to 20  &amp;nbsp &amp;nbsp : Dose as in normal renal function <LI> &lt;10 &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp : Start with small dose and increase according to response<H3> DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES  <\/H3><LI> CAPD  &amp;nbsp &amp;nbsp &amp;nbsp  &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp:Not dialysed. Dose as in GFR &lt;10 mL\/min<\/p>\n<li> HD &amp;nbsp  &amp;nbsp &amp;nbsp  &amp;nbsp &amp;nbsp  &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp &amp;nbsp :Not dialysed. Dose as in GFR &lt;10 mL\/min<LI>HDF\/high flux  &amp;nbsp :Unknown dialysability. Dose as in GFR &lt;10 mL\/min<LI>CAV\/VVHD  &amp;nbsp &amp;nbsp &amp;nbsp:Unknown dialysability. Dose as in normal renal function <H3> IMPORTANT DRUG INTERACTIONS  <\/H3>Potentially hazardous interactions with other drugs\n<li>Anaesthetics: enhanced hypotensive effect\n<li>Analgesics: increased risk of convulsions  with tramadol; enhanced hypotensive and sedative effects with opioids\n<li>Anti-arrhythmics: increased risk of  ventricular arrhythmias with anti-arrhythmics that prolong the QT interval; avoid concomitant use with amiodarone\n<li>Antibacterials: increased risk of  ventricular arrhythmias with moxifloxacin \u2013 avoid concomitant use\n<li>Antidepressants: increased level  of tricyclics, possibly increased risk of ventricular arrhythmias and antimuscarinic side effectsAnticonvulsant: antagonises  anticonvulsant effectAntimalarials: avoid concomitant use with  artemether\/lumefantrineAntipsychotics: increased risk of  ventricular arrhythmias with pimozide \u2013 avoid concomitant useAntivirals: concentration possibly  increased with ritonavirAnxiolytics and hypnotics: increased  sedative effectsAtomoxetine: increased risk of ventricular  arrhythmiasBeta-blockers: enhanced hypotensive  effect; increased risk of ventricular arrhythmias with sotalolDiuretics: enhanced hypotensive effect Lithium: increased risk of extrapyramidal  side effects and possibly neurotoxicityPentamidine: increased risk of ventricular  arrhythmiasSibutramine: increased risk of CNS  toxicity \u2013 avoid concomitant useUlcer-healing drugs: effects enhanced by  cimetidine<H3> ADMINISTRATION  <\/H3><H4> Reconstition<\/H4>\u2013<H4>  Route  <\/H4>Oral, deep IM, PR (unlicensed) <H4>  Rate of Administration  <\/H4>\u2013<H4>Comments<\/H4>Start with small doses in severe renal  impairment due to increased cerebral sensitivity<br \/>\n","protected":false},"excerpt":{"rendered":"<p>Chlorpromazine hydrochloride CLINICAL USE Anti-emetic Anxiolytic Antipsychotic Hiccups DOSE IN<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-3832","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3832","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=3832"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3832\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=3832"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=3832"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=3832"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}